Crohn's disease with infliximab treatment complicated by rapidly progressing colorectal cancer : A case report
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved..
BACKGROUND: Crohn's disease (CD) causes a range of digestive symptoms including recurrent diarrhea, abdominalgia, and flatulence, and severely impacts the quality of life of patients. Infliximab, a monoclonal antibody against tumor necrosis factor alpha, has recently been promoted as a therapeutic treatment for CD, but its safety margins remain uncertain. We report a case of rapidly progressive colorectal cancer that was diagnosed in a patient with CD who had previously been treated with infliximab.
CASE SUMMARY: This case report refers to a 40-year-old male with a 6-year history of CD. The patient underwent transverse colostomy because of inflammatory ileus in 2017. He subsequently received infliximab treatment in 2018. Ten months later, worsening contracture of the transverse colostomy was observed. Imaging tests indicated that the patient may have developed colon cancer with extensive peritoneal implantation. At the same time, colonoscopy revealed a rectal mass and pathological examination indicated well-differentiated adenocarcinoma. Palliative ileostomy was performed to improve defecation in 2019. During the operation, a small nodular mass in the mesentery of the small intestine was identified and pathological examination of the mass revealed advanced adenocarcinoma. The patient was diagnosed with advanced colorectal cancer and administered palliative chemotherapy. He died in June 2020.
CONCLUSION: We stress the importance of recognizing the possible occurrence of malignance in patients with CD receiving infliximab.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
World journal of gastrointestinal oncology - 13(2021), 4 vom: 15. Apr., Seite 305-311 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiao, Lin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 24.04.2021 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4251/wjgo.v13.i4.305 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324432437 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324432437 | ||
| 003 | DE-627 | ||
| 005 | 20231225190318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4251/wjgo.v13.i4.305 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1081.xml |
| 035 | |a (DE-627)NLM324432437 | ||
| 035 | |a (NLM)33889281 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xiao, Lin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Crohn's disease with infliximab treatment complicated by rapidly progressing colorectal cancer |b A case report |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.04.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Crohn's disease (CD) causes a range of digestive symptoms including recurrent diarrhea, abdominalgia, and flatulence, and severely impacts the quality of life of patients. Infliximab, a monoclonal antibody against tumor necrosis factor alpha, has recently been promoted as a therapeutic treatment for CD, but its safety margins remain uncertain. We report a case of rapidly progressive colorectal cancer that was diagnosed in a patient with CD who had previously been treated with infliximab | ||
| 520 | |a CASE SUMMARY: This case report refers to a 40-year-old male with a 6-year history of CD. The patient underwent transverse colostomy because of inflammatory ileus in 2017. He subsequently received infliximab treatment in 2018. Ten months later, worsening contracture of the transverse colostomy was observed. Imaging tests indicated that the patient may have developed colon cancer with extensive peritoneal implantation. At the same time, colonoscopy revealed a rectal mass and pathological examination indicated well-differentiated adenocarcinoma. Palliative ileostomy was performed to improve defecation in 2019. During the operation, a small nodular mass in the mesentery of the small intestine was identified and pathological examination of the mass revealed advanced adenocarcinoma. The patient was diagnosed with advanced colorectal cancer and administered palliative chemotherapy. He died in June 2020 | ||
| 520 | |a CONCLUSION: We stress the importance of recognizing the possible occurrence of malignance in patients with CD receiving infliximab | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Case report | |
| 650 | 4 | |a Colon cancer | |
| 650 | 4 | |a Crohn's disease | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Infliximab | |
| 650 | 4 | |a Rectum cancer | |
| 650 | 4 | |a Tumor necrosis factor | |
| 700 | 1 | |a Sun, Lie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Kang |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Yi-Sheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of gastrointestinal oncology |d 2009 |g 13(2021), 4 vom: 15. Apr., Seite 305-311 |w (DE-627)NLM204375533 |x 1948-5204 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:4 |g day:15 |g month:04 |g pages:305-311 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4251/wjgo.v13.i4.305 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 4 |b 15 |c 04 |h 305-311 | ||